The major shareholder and actual controller of jiangsu hengrui Pharmaceutical Group Co., Ltd. is Sun Piaoyang, who holds 89.22% of the shares of jiangsu hengrui Pharmaceutical Group Co., Ltd.
Hengrui Pharma was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical company focusing on the research, development, production and promotion of high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases and cardiovascular diseases. It is one of the most innovative pharmaceutical leading enterprises in China.
For more than 50 years, Hengrui Pharma has always adhered to the initial intention of serving patients, strived to ensure the healthy life and quality of life of patients, overcome difficulties and promote the high-quality development of the pharmaceutical industry. In the list of the top 50 global pharmaceutical companies in 2022 published by Pharmaceutical Manager magazine, Hengrui Pharma ranked 32nd, setting a new record for pharmaceutical companies in China. The company has been selected as one of the top 100 pharmaceutical enterprises in China for many years, and in 2022, it was ranked as the best industrial enterprise in China pharmaceutical R&D product line again.
Hengrui Pharma's development strategy
As a leading pharmaceutical R&D enterprise in China, Hengrui Pharma earnestly fulfills its corporate social responsibility and continuously improves the accessibility of high-quality drugs. The company actively supports the national medical insurance measures to benefit the people, and 93 products have successively entered the national medical insurance catalogue, including karizumab, leviathamide and other 1 1 innovative drugs, so that domestic patients can "afford" new and good drugs.
Steadily promoting internationalization is Hengrui Pharma's long-term development strategy. At present, the company's pharmaceutical products have entered more than 40 countries, and continue to accelerate the development of the global market, paying attention to emerging markets. The company has authorized a number of innovative drugs with independent intellectual property rights, such as Karelizumab, SHR0302 and SHR2554, and actively exported innovative achievements overseas. The company has obtained more than 20 registration documents in Europe, America and Japan, including injections, oral preparations and inhaled anesthetics, which has improved the drug accessibility of patients in different regions of the world.
Refer to the above contents: official website, Hengrui Pharma-About Hengrui